Core Viewpoint - As of January 13, 2026, Kangtong Medical (301515) closed at 26.65 yuan, marking a 5.67% increase with a turnover rate of 20.33% and a trading volume of 133,300 hands, resulting in a transaction amount of 349 million yuan [1]. Group 1: Financial Performance - For the first three quarters of 2025, Kangtong Medical reported a main revenue of 344 million yuan, a year-on-year decrease of 30.06% [3]. - The net profit attributable to shareholders was -10.21 million yuan, reflecting a year-on-year decline of 150.92% [3]. - The net profit after deducting non-recurring gains and losses was -12.87 million yuan, down 176.82% year-on-year [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 79.12 million yuan, an increase of 42.81% year-on-year [3]. - The single-quarter net profit attributable to shareholders was -1.80 million yuan, a decrease of 138.94% year-on-year [3]. - The single-quarter net profit after deducting non-recurring gains and losses was -2.60 million yuan, down 182.34% year-on-year [3]. - The company's debt ratio stood at 40.94%, with investment income of -0.18 million yuan and financial expenses of 0.54 million yuan, while the gross profit margin was 22.45% [3]. Group 2: Capital Flow - On January 13, 2026, the net inflow of main funds was 15.72 million yuan, accounting for 4.51% of the total transaction amount [1]. - Retail investors experienced a net outflow of 10.38 million yuan, representing 2.98% of the total transaction amount [1]. - The financing data indicated a financing buy of 50.28 million yuan and a financing repayment of 30.23 million yuan, resulting in a net financing purchase of 20.05 million yuan, with a cumulative net purchase of 52.10 million yuan over three consecutive days [2].
港通医疗（301515）1月13日主力资金净买入1572.24万元